...
机译:Bendamustine与Gemcitabine和Vinorelbine(Begev)的组合是一种有效的预处理,复发/难治性霍奇金淋巴瘤患者的有效方案:多中心,回顾性真实研究
Humanitas Res Hosp Humanitas Canc Ctr Oncol &
Hematol Milan Italy;
Sapienza Univ Hematol Rome Italy;
Fdn IRCCS Ist Nazl Tumori Div Hematol Milan Italy;
Humanitas Res Hosp Humanitas Canc Ctr Oncol &
Hematol Milan Italy;
Humanitas Res Hosp Humanitas Canc Ctr Hematol Milan Italy;
Humanitas Res Hosp Humanitas Canc Ctr Oncol &
Hematol Milan Italy;
Humanitas Res Hosp Humanitas Canc Ctr Oncol &
Hematol Milan Italy;
Fdn IRCCS Ist Nazl Tumori Div Hematol Milan Italy;
Fdn IRCCS Ist Nazl Tumori Div Hematol Milan Italy;
Univ Insubria Dept Hematol Varese Italy;
Humanitas Res Hosp Nucl Med Milan Italy;
Univ Roma La Sapienza Dept Cellular Biotechnol &
Hematol Rome Italy;
Univ Roma La Sapienza Dept Cellular Biotechnol &
Hematol Rome Italy;
Univ Roma La Sapienza Dept Cellular Biotechnol &
Hematol Rome Italy;
Humanitas Res Hosp Biostat Unit Milan Italy;
Humanitas Res Hosp Humanitas Canc Ctr Hematol Milan Italy;
Univ Insubria Dept Hematol Varese Italy;
Humanitas Univ Dept Biomed Sci Milan Italy;
Fdn IRCCS Ist Nazl Tumori Milano Milan Italy;
Humanitas Univ Dept Biomed Sci Milan Italy;
Humanitas Univ Dept Biomed Sci Milan Italy;
机译:Bendamustine与Gemcitabine和Vinorelbine(Begev)的组合是一种有效的预处理,复发/难治性霍奇金淋巴瘤患者的有效方案:多中心,回顾性真实研究
机译:Bendamustine与Gemcitabine和Vinorelbine的组合是一种有效的方案,作为在复发或难治性霍奇金淋巴瘤复发或难治性霍奇金淋巴瘤的自体干细胞移植之前:多中心期II研究的最终结果
机译:五年的存活率和耐用性,使用Begev方案(Bendamustine,Gemcitabine和Vinorelbine)作为拯救疗法在复发/难以经典霍奇金淋巴瘤之前作为救助治疗的救生疗法
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:吉西他滨长春瑞滨聚乙二醇脂质体阿霉素和brentuximab的顺序组合作为过渡方案治疗复发或难治性霍奇金淋巴瘤
机译:Bendamustine与Gemcitabine和Vinorelbine的组合是一种有效的方案,作为在复发或难治性霍奇金淋巴瘤复发或难治性霍奇金淋巴瘤的自体干细胞移植之前:多中心期II研究的最终结果